How sponsors can recognize material underperformance, diagnose root causes, and select the least disruptive path to recovery. Clinical trials rarely move from “on track” to “in crisis” overnight. Warning signs usually emerge gradually: si...
The P95 Julius Clinical team recently joined researchers, sponsors, clinicians, and industry leaders in Munich for ESC Congress 2026. Across scientific sessions, new clinical guidance, and industry discussions, several themes emerged that could in...
Real-world evidence (RWE) can help neuroscience sponsors account for disease heterogeneity, identify development risks earlier, and build more precise evidence strategies from Day 1.For decades, Parkinson’s disease has often been approached ...
Rescue Study Expertise for At-Risk Clinical Trials When clinical studies face enrollment shortfalls, startup delays, operational challenges, or CRO underperformance, sponsors need more than additional resources. They need an experienced partner c...
How Strategic Site Engagement and Patient-Centric Retention Supported Study Success A Phase II Alzheimer's disease study evaluating an investigational therapy faced significant operational challenges, including a complex biomarker-driven design r...
The August 2026 FDA approval of TAUKLARIFY™ (florquinitau F 18 injection) is more than a regulatory milestone. It reflects a broader shift in Alzheimer's research toward biomarker-driven disease characterization and brings tau pathology into sha...
With obesity affecting more than one billion people globally and the market for obesity therapeutics projected to grow dramatically over the next decade, the stakes for sponsors have never been higher. Driven by breakthrough therapies, rapid marke...
Parkinson’s Disease CRO Expertise for Complex Clinical Trials As Parkinson’s disease research advances toward earlier intervention, disease modification, and prevention-focused approaches, sponsors need a partner with deep therapeutic experti...
Drawing on the experience and perspectives of Prof. Dr. Manuel Castro Cabezas, Scientific Officer at P95 Julius Clinical, and Prof. Dr. Diederick (Rick) E. Grobbee, Chief Scientific Officer at P95 Julius Clinical, this article explores how sponsor...
As the search for reliable biomarkers in neurodegenerative diseases continues, researchers are working to better understand how disease-related proteins can support diagnosis, monitoring, and future treatment development. A newly published study i...
"*" indicates required fields
"*" indicates required fields
